Analysis of seven characteristics and trend of world biomedical industry

[market analysis of China Pharmaceutical network] from the perspective of the development trend of the world's biomedical industry, it is currently at the beginning stage of large-scale industrialization of biomedical technology It is expected to enter a rapid development period after 2020 and gradually become the leading industry of the world economy In general, the development of the world's biomedical industry shows the following seven characteristics and trends: (1) the industrialization process of biomedical industry has been significantly accelerated by nearly 20 In recent years, modern biotechnology, represented by gene engineering, cell engineering and enzyme engineering, has developed rapidly Major technologies such as human genome project have made breakthroughs one after another Modern biotechnology has been widely used in medical treatment, and the process of biomedical industrialization has accelerated significantly There are more than 2200 biotechnological drugs under development in the world, and more than 1700 of them have entered clinical trials The rapid increase in the number of biotechnological drugs shows that the industrialization of the world's pharmaceutical biotechnologies is gradually entering the investment harvest period in the 21st century, and the global biomedical industry is growing rapidly Since the 1990s, the global sales of biopharmaceuticals have grown at an average annual rate of more than 30%, which is much higher than the growth rate of less than 10% in the global pharmaceutical industry Biomedical industry is developing rapidly from high-tech industry with potential to high-tech pillar industry (2) the development of biomedicine shows a significant trend of centralization First, a few developed countries occupy a proportion in the global biomedical market and are in the leading position of the industry In the world drug market, the share of the three major drug markets of the United States, Europe and Japan has exceeded 80% From the perspective of biotechnology industry, the total number of global biotechnology companies has reached 4362, of which the total number of biotechnology companies is mainly concentrated in Europe and the United States, accounting for 76% of the global total The sales of European and American companies account for 93% of the global sales of biotechnology companies, while the sales of Asia Pacific region only account for about 3% of the global sales The United States is the leader of biotechnology industry, and other countries account for more than 70% of the world's developed products and market sales Second, large multinational companies dominate the world pharmaceutical market The position of multinational enterprises in the global pharmaceutical market is increasing, and their proportion is growing The concentration of modern pharmaceutical industry is increasing year by year, and the monopoly degree of multinational enterprises is increasing Third, in the field of product market, the market concentration of single product sales is also increasing (III) developed countries have formed a number of biomedical industry intensive areas Driven by the rapid development of biotechnology industry, after years of development and market competition, as well as the government's timely guidance, many developed countries have gradually formed a bio industry cluster area in the areas of technology, talent and capital intensive, thus forming a relatively complete bio pharmaceutical industry chain and industrial cluster The United States has formed five biotechnology industrial areas, namely San Francisco, Boston, Washington, North Carolina and San Diego Among them, Silicon Valley's biotechnology industry employees account for more than half of the U.S biotechnology industry employees, sales revenue accounts for 57% of the U.S biotechnology industry, R & D investment accounts for 59%, and its sales volume grows at nearly 40% every year In addition to the United States and other countries, Cambridge genome Park in the United Kingdom, gene Valley in the southern suburb of Paris in France, biotechnology demonstration area in Germany, Bangalore bio Park in India, etc gather a large number of institutions including biological companies, research, technology transfer centers, banks, investment, services, etc., providing a large number of employment opportunities and most of the output value These biotechnology industry clusters have emerged in the industrial structure of these countries and regions, and have made important contributions to the expansion of industrial scale and the enhancement of industrial competitiveness (IV) biotechnological pharmaceuticals and natural medicines have broad prospects Driven by many heavyweight products, the demand for antibiotics is still growing Generally speaking, the market for traditional chemicals will remain huge in the next 10 years, accounting for about 70% of the whole pharmaceutical market Due to the rapid development of biotechnology, the change of people's medical consumption structure and the safety performance requirements of drugs, the dominant position of chemicals in the drug market is facing serious challenges Emerging biological drugs will rise rapidly in the drug market, and biological drugs have become the top priority of drug research and development At the same time, more and more high-tech and biotechnology will be applied to In the improvement of germplasm of natural medicinal materials, natural medicines will grow more rapidly (5) the R & D investment has been increasing, and the climax of market M & A and restructuring has occurred repeatedly The biomedical industry has the characteristics of high investment, high income, high risk and long cycle, which requires high investment as the condition for industry entry and sustainable development In order to cope with the rapid change of scientific and technological innovation and the increasingly fierce competition in international science and technology, large international pharmaceutical enterprises are scrambling to increase investment in scientific research According to statistics, the proportion of R & D investment in sales of large pharmaceutical companies in the world is between 9% and 18%, while the proportion of R & D investment in sales of biotechnology companies is more than 20% For pure biotechnology companies, the proportion of R & D investment is larger In order to establish a global production and sales network, reduce costs to a large extent, acquire new drugs or master new technologies directly, mergers and reorganizations among biotechnology companies, biotechnology companies, large pharmaceutical companies and large pharmaceutical companies are very active in the world The upsurge of M & A and restructuring in the global biomedical industry has greatly improved the ability of developed countries and multinational companies to seize the market, monopolize technology and obtain excess profits (VI) strategic technology alliance has become a successful model for new drug development New drug discovery is a complex system project integrating knowledge and technology of molecular biology, genomics and systems biology The initial investment is huge and the risk is also great It requires alliance and joint investment between multinational pharmaceutical giants, biotechnology companies and pharmaceutical companies According to the data, half of the approved biotech drugs have been developed through cooperation This trend of strengthening cooperation is mainly manifested in: first, strategic alliance promotes the transformation of biotechnology to industrialization Since most biotechnology products and production technologies are in the hands of new biotech enterprises, in order to maintain the sustainability of new drug research and development, almost all pharmaceutical enterprises have formed strategic alliances with biotech companies These small expert biotech companies with strong technical force carry out technological development and innovation, and through cooperative development, obtain the production technology of biotech drugs Right of production, this model has successfully promoted the healthy development of biomedical industry Second, innovative drug development adopts outsourcing strategy In order to shorten the development time of innovative drugs, in recent years, many biotechnology and pharmaceutical companies have begun to form technical alliances with some small companies to subcontract research and development contents with strong technology to small companies with research strength According to the statistics of centerwatch, at present, cro has undertaken nearly 1 / 3 of the organization work of new drug development in the U.S market Cro has become an important part of the pharmaceutical industry chain, and it has been highly valued by biotechnology and pharmaceutical companies with its low-cost, specialized and efficient operation (7) governments of all countries attach great importance to the development of biological industry Many countries regard the biological technology industry as a strategic industry of priority development in the 21st century, as an important means to improve their competitiveness They have formulated development plans, strengthened leadership, recruited talents, and increased policy support and capital investment in the biological medicine industry For example, the U.S regards the biomedical industry as a new economic growth point, implements the "biotechnology industry incentive policy" and continuously increases investment in biotechnology research and development and industrialization; Japan's "bio industry builds the country" strategy; the EU's Sixth Framework for science and technology development uses 45% of research and development funds in biotechnology and related fields, As early as 1981, the British government set up the "biotechnology coordination Steering Committee" to take measures to promote industry, universities and scientific research institutions to increase investment in biotechnology development and research; Singapore formulated the "five years to join the ranks of biotechnology" plan, and within five years will allocate S $3 billion to support the life science and biotechnology industry; India has set up a Ministry of biotechnology, with an annual investment of US $60 million to US $70 million for biotechnology and pharmaceutical research; In the 1990s, when Cuba's economy was very difficult, it implemented the "biotechnology investment plan" and invested US $1 billion to develop the biotechnology industry Over the past 10 years, it has achieved more than 400 items The export of biomedical products to more than 20 countries, such as the United Kingdom, has directly promoted the prosperity of Cuba's economy Original title: analysis of the development characteristics and trend of the world's biomedical industry